MedTrace Logo

Stage I/II Nasal NK Cell Lymphoma

NCT01321008 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-02-05

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.

Conditions

Interventions

RADIATION

Radiation

50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.

DRUG

Cyclophosphamide

750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.

DRUG

Doxorubicin

50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.

DRUG

Vincristine

1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.

DRUG

Prednisone

100 mg by mouth daily on Days 1-5 of a 21 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Bouthaina Dabaja, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01321008 on ClinicalTrials.gov